RxSight (NASDAQ:RXST) has been analyzed by 8 financial analysts, showing a range of opinions from bullish to bearish. Recent assessments indicate an upward trend in price targets, with an average 12-month target of $59.12, reflecting a 21.0% increase from the previous average of $48.86. Analysts from firms including Needham, Stifel, JP Morgan, and Oppenheimer have adjusted their ratings and price targets, suggesting a positive outlook for RxSight. The company, specializing in intraocular lens technology post-cataract surgery, has shown a revenue growth of 77.65% as of December 31, 2023, but faces challenges with profitability and asset utilization.